Wells Fargo & Company Boosts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $37.00

Celldex Therapeutics (NASDAQ:CLDX) had its target price increased by Wells Fargo & Company from $35.00 to $37.00 in a report published on Monday morning, Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the company. HC Wainwright reissued a buy rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research report on Monday. Wolfe Research assumed coverage on shares of Celldex Therapeutics in a research report on Tuesday, June 11th. They set an outperform rating and a $51.00 price target for the company. Stifel Nicolaus started coverage on shares of Celldex Therapeutics in a research report on Tuesday, June 18th. They issued a buy rating and a $58.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an overweight rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, July 30th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average price target of $63.83.

Celldex Therapeutics Price Performance

Shares of Celldex Therapeutics stock opened at $32.33 on Monday. The stock has a market cap of $2.13 billion, a price-to-earnings ratio of -11.34 and a beta of 1.58. The firm’s 50-day moving average is $36.54 and its two-hundred day moving average is $38.75. Celldex Therapeutics has a 1 year low of $22.11 and a 1 year high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. The firm had revenue of $2.50 million for the quarter, compared to the consensus estimate of $1.13 million. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. On average, equities analysts expect that Celldex Therapeutics will post -2.39 earnings per share for the current year.

Insider Activity at Celldex Therapeutics

In other Celldex Therapeutics news, CFO Samuel Bates Martin sold 35,000 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $34.05, for a total transaction of $1,191,750.00. Following the transaction, the chief financial officer now owns 25,128 shares in the company, valued at approximately $855,608.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Celldex Therapeutics news, CFO Samuel Bates Martin sold 35,000 shares of the business’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $34.05, for a total transaction of $1,191,750.00. Following the sale, the chief financial officer now owns 25,128 shares in the company, valued at approximately $855,608.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Margo Heath-Chiozzi sold 38,719 shares of the firm’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $34.07, for a total value of $1,319,156.33. Following the completion of the transaction, the senior vice president now owns 7,094 shares of the company’s stock, valued at $241,692.58. The disclosure for this sale can be found here. Insiders sold 266,332 shares of company stock valued at $9,155,821 in the last three months. 3.80% of the stock is owned by insiders.

Institutional Trading of Celldex Therapeutics

Several large investors have recently made changes to their positions in CLDX. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Celldex Therapeutics during the second quarter worth $76,000. Strs Ohio grew its holdings in Celldex Therapeutics by 92.9% during the fourth quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 1,300 shares during the period. Headlands Technologies LLC purchased a new position in Celldex Therapeutics during the first quarter valued at approximately $147,000. CANADA LIFE ASSURANCE Co lifted its holdings in Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 955 shares during the period. Finally, Aigen Investment Management LP purchased a new stake in Celldex Therapeutics in the 4th quarter worth approximately $251,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.